Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cell-mediated Immune Responses01:40

Cell-mediated Immune Responses

83.2K
Overview
83.2K
Tumor Immunotherapy01:27

Tumor Immunotherapy

1.7K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.7K
Diversity of Antigen Receptors01:28

Diversity of Antigen Receptors

1.3K
Antigen receptors are essential components of the immune system crucial in defending the body against foreign invaders. These receptors are present on the surface of B and T cells, enabling them to recognize antigens and mount an appropriate immune response.
Before encountering any antigen, lymphocytes express these receptors. On B cells, the antigen receptor is a membrane-bound antibody molecule called BCR; on T cells, it is a T cell receptor or TCR. B and T cell receptors are composed of two...
1.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The Effect of Prevaccination Analgesics on Influenza Vaccine Immunogenicity and Effectiveness.

The Journal of infectious diseases·2026
Same author

Comparison of Environmental Microbiomes, Resistomes and Plasmidomes from a Human Tertiary Hospital and Companion Animal Veterinary Hospital in London, UK.

Antibiotics (Basel, Switzerland)·2026
Same author

Good communication with adults with learning disabilities in long-term care settings: A realist review.

Disability and health journal·2026
Same author

Influenza-like illness in cigarette smokers and electronic-cigarette users: a secondary analysis from the PAIVED study.

Frontiers in public health·2026
Same author

Clinical validation of a tissue-agnostic genome-wide methylome enrichment assay to monitor response to pembrolizumab.

NPJ precision oncology·2026
Same author

Healthcare Workers Have More Frequent and Less Severe Influenza-Like Illness Than Non-healthcare Workers: Findings From the PAIVED Study.

Open forum infectious diseases·2026

Related Experiment Video

Updated: Jan 3, 2026

Non-Viral Engineering of Primary Human T Cells via Homology-Mediated End-Joining Targeted Integration of Large DNA Templates
06:10

Non-Viral Engineering of Primary Human T Cells via Homology-Mediated End-Joining Targeted Integration of Large DNA Templates

Published on: May 9, 2025

834

Repurposing endogenous immune pathways to tailor and control chimeric antigen receptor T cell functionality.

Mohit Sachdeva1, Brian W Busser1, Sonal Temburni1

  • 1Cellectis, Inc., 430 East 29th Street, New York, NY, 10016, USA.

Nature Communications
|November 15, 2019
PubMed
Summary
This summary is machine-generated.

Researchers engineered chimeric antigen receptor (CAR) T-cells by repurposing immune pathways. This strategy enhances CAR T-cell antitumor activity and survival in a controlled, antigen-dependent manner.

More Related Videos

Generation of Human Chimeric Antigen Receptor Regulatory T Cells
10:29

Generation of Human Chimeric Antigen Receptor Regulatory T Cells

Published on: January 3, 2025

2.2K
Transduction and Expansion of Primary T Cells in Nine Days with Maintenance of Central Memory Phenotype
08:49

Transduction and Expansion of Primary T Cells in Nine Days with Maintenance of Central Memory Phenotype

Published on: March 18, 2020

11.5K

Related Experiment Videos

Last Updated: Jan 3, 2026

Non-Viral Engineering of Primary Human T Cells via Homology-Mediated End-Joining Targeted Integration of Large DNA Templates
06:10

Non-Viral Engineering of Primary Human T Cells via Homology-Mediated End-Joining Targeted Integration of Large DNA Templates

Published on: May 9, 2025

834
Generation of Human Chimeric Antigen Receptor Regulatory T Cells
10:29

Generation of Human Chimeric Antigen Receptor Regulatory T Cells

Published on: January 3, 2025

2.2K
Transduction and Expansion of Primary T Cells in Nine Days with Maintenance of Central Memory Phenotype
08:49

Transduction and Expansion of Primary T Cells in Nine Days with Maintenance of Central Memory Phenotype

Published on: March 18, 2020

11.5K

Area of Science:

  • Immunology
  • Molecular Biology
  • Cancer Research

Background:

  • Chimeric antigen receptor (CAR) T-cell therapy shows promise for cancer treatment.
  • Enhancing CAR T-cell potency requires tight regulatory control to prevent adverse effects.
  • Immune pathways offer naturally regulated genes suitable for repurposing potent functionalities.

Purpose of the Study:

  • To explore repurposing T-cell activation pathway genes (TCR, CD25, PD1) to create controlled CAR T-cells.
  • To develop CAR T-cells with enhanced, regulated antitumor activity.
  • To investigate antigen concentration-dependent cytokine secretion for improved therapeutic control.

Main Methods:

  • CAR gene inserted into the T-cell receptor alpha (TRAC) gene (TRACCAR).
  • Interleukin-12 (IL-12P70) inserted into IL2Rα or PDCD1 genes.
  • Evaluated TRACCAR T-cell cytotoxicity and survival in tumor-bearing mice.

Main Results:

  • Achieved transient, antigen concentration-dependent IL-12P70 secretion.
  • Demonstrated increased TRACCAR T-cell cytotoxicity.
  • Observed extended survival in tumor-bearing mice treated with engineered CAR T-cells.

Conclusions:

  • Repurposing gene networks within cellular pathways enables controlled expression of potent CAR T-cell functionalities.
  • This strategy allows for the generation of "smart" CAR T-cells that integrate biological signals for therapeutic output.
  • The approach offers a framework for developing more sophisticated and safer CAR T-cell therapies.